Acute Rejection Risk in Kidney Transplant Recipients on Steroid-Avoidance Immunosuppression Receiving Induction With Either Antithymocyte Globulin or Basiliximab

Transplantation Proceedings

Volumn 38, Issue 5, 2006, Pages 1307-1313

  Heilman, R L ^a   Reddy, K S ^a   Mazur, M J ^a   Moss, A A ^a   Post, D J ^a   Petrides, S ^a   Mulligan, D C ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BASILIXIMAB; METHYLPREDNISOLONE ACETATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY;

ACUTE GRAFT REJECTION; ADULT; AGED; ARTICLE; BK VIRUS; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DRUG INDICATION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; KIDNEY BIOPSY; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PARVOVIRUS INFECTION; PNEUMONIA; PRIORITY JOURNAL; RISK ASSESSMENT; SEPSIS; TREATMENT OUTCOME; URINARY TRACT INFECTION; VIRUS INFECTION;

ACUTE DISEASE; ADRENAL CORTEX HORMONES; ADULT; AGED; ANIMALS; ANTIBODIES, MONOCLONAL; ANTILYMPHOCYTE SERUM; FEMALE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PATIENT SELECTION; RABBITS; RECOMBINANT FUSION PROTEINS; RISK FACTORS;

EID: 33745186177     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2006.02.116     Document Type: Article

References (19)

1. Kasiske B.L., Chakkera H.A., Louis T.A., et al. A meta-analysis of immunosuppression withdrawal trials in renal transplantation. J Am Soc Nephrol 11 (2000) 1910
2. Vincenti F., Monaco A., Grinyo J., et al. Multicenter randomized prospective trial of steroid withdrawal in renal transplant recipients receiving basiliximab, cyclosporine microemulsion and mycophenolate mofetil. Am J Transplant 3 (2003) 306
3. Opelz G., Dohler B., and Laux G. Long-term prospective study of steroid withdrawal in kidney and heart transplant recipients. Am J Transplant 5 (2005) 720
4. Matas A.J., Ramcharan T., Paraskevas S., et al. Rapid discontinuation of steroids in living donor kidney transplantation. a pilot study. Am J Transplant 1 (2001) 278
5. Khwaja K., Asolati M., Harmon J., et al. Outcome at 3 years with a prednisone-free maintenance regimen. a single-center experience with 349 kidney transplant recipients. Am J Transplant 4 (2004) 980
6. Racusen L.C., Solez K., Colvin R.B., et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 55 (1999) 713
7. Bradley B.A. Rejection and recipient age. Transpl Immunol 10 (2002) 125
8. Meier-Kriesche H.U., Ojo A., Hanson J., et al. Increased immunosuppressive vulnerability in elderly renal transplant recipients. Transplantation 69 (2000) 885
9. Neylan J.F., and FK506 Kidney Transplant Study Group. Racial differences in renal transplantation after immunosuppression with tacrolimus versus cyclosporine. Transplantation 65 (1998) 515
10. Nankivell B.J., Borrows R.J., Fung C.L., et al. The natural history of chronic allograft nephropathy. N Engl J Med 349 (2003) 2326
11. Nankivell B.J., Borrows R.J., Fung C.L., et al. Natural history, risk factors, and impact of subclinical rejection in kidney transplantation. Transplantation 78 (2004) 242
12. Rush D.N., Jeffery J.R., and Gough J. Sequential protocol biopsies in renal transplant patients. clinico-pathological correlations using the Banff schema. Transplantation 59 (1995) 511
13. Hardinger K.L., Schnitzler M.A., Miller B., et al. Five-year follow up of thymoglobulin versus ATGAM induction in adult renal transplantation. Transplantation 78 (2004) 136
14. Bustami R.T., Ojo A.O., Wolfe R.A., et al. Immunosuppression and the risk of post-transplant malignancy among cadaveric first kidney transplant recipients. Am J Transplant 4 (2004) 87
15. Cherikh W.S., Kauffman H.M., McBride M.A., et al. Association of the type of induction immunosuppression with posttransplant lymphoproliferative disorder, graft survival, and patient survival after primary kidney transplantation. Transplantation 76 (2003) 1289
16. Ducloux D., Kazory A., Challier B., et al. Long-term toxicity of antithymocyte globulin induction may vary with choice of agent. a single-center retrospective study. Transplantation 77 (2004) 1029
17. Meier-Kriesche H.U., Arndorfer J.A., and Kaplan B. Association of antibody induction with short- and long-term cause-specific mortality in renal transplant recipients. J Am Soc Nephrol 13 (2002) 769
18. Lebranchu Y., Bridoux F., Buchler M., et al. Immunoprophylaxis with basiliximab compared with antithymocyte globulin in renal transplant patients receiving MMF-containing triple therapy. Am J Transplant 2 (2002) 48
19. Mourad G., Rostaing L., Legendre C., et al. Sequential protocols using basiliximab versus antithymocyte globulins in renal-transplant patients receiving mycophenolate mofetil and steroids. Transplantation 78 (2004) 584